Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genetic Testing Solutions > ERA

ERA® Endometrial Receptivity Analysis

Maximize the chances of pregnancy without losing valuable embryos

  • Technical Overview
  • Documentation
  • Scientific evidence
  • I’m not a health specialist

ERA is the only endometrial receptivity test supported by a RCT*.

3 out of 10 patients have their implantation window shifted**

Optimised implantation

With EmbryoGlue® and ERA®.

Learn more about Optimised implantation →

Interested in learning more?

Request information
Or Email us at supportspain@igenomix.com

Overview

  • ERA®
  • Reasons
  • Benefits
  • Indications

What is the ERA® (Endometrial Receptivity Analysis) test?

  • ERA® test, developed and patented by Igenomix (PCT/ ES2009/000386), is a test designed to evaluate endometrial receptivity.  
  • ERA® is the first diagnostic test that determines each woman’s unique personalized embryo transfer timing, therefore synchronizing the embryo transfer with the individualized window of implantation.

What is the procedure?

ERA® Endometrial Receptivity Analysis
ERA® Endometrial Receptivity Analysis

1 – Learning from more than 200,000 women, the highest number of cases in the market

  • With over 200.000 women worldwide having undergone the test, the ERA predictor algorithm is based on artificial intelligence, allowing for continual refinements, and learning from those women who have successfully had pregnacies following the ERA recommendation.
  • ERA is the test with the most data published about clinically monitoring patients during pregnancy, enabling us to make a personalised embryo transfer recommendation with the highest accuracy.

2 – ERA is the endometrial receptivity test powered by most scientific background in the market

  • 16 external publications supporting ERA and 6 internal with convincing clinical outcome.
  • Since it was developed and patented in 2009, both the Igenomix research team and independent clinics have written numerous publications showing the results of carrying out a personalised embryo transfer using the ERA.
  • The first endometrial receptivity test with UNE-EN ISO 15189 accreditation.

3 – The highest published clinical rates compared to any other test in the market

  • In the recurrent implantation failure (RIF) population, patients who underwent a personalized embryo transfer (pET) guided by ERA had significantly increased clinical outcomes versus those patients who did not undergo a pET guided by ERA. (Jia et al., 2022).
  • ERA is the endometrial receptivity test with the highest published clinical rates for patients with RIF. (Jia et al., 2022 vs Ohara et al., 2022)
  • RIF patients who undergo a pET guided by ERA found to have similar outcomes to those achieved by good prognosis patients. (Liu et al., 2022).

4 – Clinical support all the way. The largest Scientific community by your side

  • Igenomix maintains the strongest scientific team in the market, consisting of 15 global Scientific Advisors, dedicated endometrial specialists, and in-house clinicians to support you all the way.

5 – The originals and the first to approach endometrial health with a 360 view.

  • More than 65.000 EndomeTRIO (ERA, EMMA, and ALICE) samples analyzed in 5 years. Combined over 26 publications supporting our endometrial tests.
  • The endometrium is important: an imbalance in the endometrial flora caused by a low level of Lactobacillus and the presence of some pathogens is linked to worse reproductive results. (Moreno et al, AJOG 2016).
  • The presence of pathogenic bacteria in the endometrium can cause chronic endometritis, a silent illness suffered by 30% of women with infertility problems.(Cicinelli et al, Reprod Sci 2014).
  • By carrying out the EMMA and ALICE tests in addition to the ERA, we can discount or solve important causes of implantation failure and recurrent miscarriage based on just one sample of the endometrium.
ERA® Endometrial Receptivity Analysis

Why use ERA® test?

  • ERA maximizes your patient’s chances of pregnancy.
  • This molecular diagnostic tool uses NGS to analyze the expression level of 248 genes related to the status of endometrial receptivity.
  • ERA is backed by 25 publications; 16 from Igenomix and 9 external publications.
  • Proprietary algorithm based on machine learning that minimizes the need for second biopsy (90% of cases).
  • Allows clinicians to identify transition phases with 12 hours shifts.

Who should use ERA® Endometrial Receptivity Analysis test?

  • ERA® test is indicated for patients with recurrent implantation failure

When is the second endometrial biopsy needed?

90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:

  • Patients with a “Pre-receptive” result needing 2 more days with progesterone.
  • Patients with a “Post-receptive” result.

Test limitations

ERA® Endometrial Receptivity Analysis

Documentation

  • ERA® Specialist's documents

Clinical Sheets

Download

Brochure

Download

Publications List

Download

EndomeTRIO Manual

Download

Instructions

Download

RCT Key Findings

Download

Retraction of a meta analysis

Download

Scientific evidence

References:

* Barbakadze et al., Assessment of theRole of Endometrial ReceptivityAnalysis in Enhancing AssistedReproductive Technology Outcomesfor Advanced-Age Patients. Cureus vol.16,6 e62949. 23 Jun. 2024,doi:10.7759/cureus.62949.

Key Studies

Visit the ERA insight Hub – International to download the complete ERA Publication List and explore all related studies.

  • Independent
  • Igenomix

Assessment of the Role of Endometrial Receptivity Analysis in Enhancing Assisted Reproductive Technology Outcomes for Advanced-Age Patients.

Barbakadze T, Shervashidze M, Charkviani T, et al.
Cureus. 2024;16(6):e62949. Published 2024 Jun 23. doi:10.7759/cureus.62949

The Clinical Efficacy of Personalized Embryo Transfer Guided by the Endometrial Receptivity Array/Analysis on IVF/ICSI Outcomes: A Systematic Review and Meta-Analysis.

Liu Z, Liu X, Wang M, Zhao H, He S, Lai S. et al
Front Physiol. 2022;13:841437. Published 2022 Apr 27. doi:10.3389/fphys.2022.841437

Comparison of the Effectiveness of Endometrial Receptivity Analysis (ERA) to Guide Personalized Embryo Transfer with Conventional Frozen Embryo Transfer in 281 Chinese Women with Recurrent Implantation Failure.

Jia Y, Sha Y, Qiu Z, Guo Y, Tan A, Huang Y. et al
Med Sci Monit. 2022;28:e935634. Published 2022 Mar 22. doi:10.12659/MSM.935634

Role of endometrial receptivity array in current implantation failure.

Samadhiya R, Swarnkar G, Singh A, Chittawar P.
Fertility Science and Research, 8(2), 180

Clinical outcomes following endometrial receptivity assessment-guided personalized euploid embryo transfer in patients with previous implantation failures.

Ruiz-Alonso, M., Gómez, C., Stankewicz, T. et al.
Scientific reports vol. 15,1 16967. 15 May. 2025, doi:10.1038/s41598-025-01056-5

A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF.

Simón, C., Gómez, C., Cabanillas, S., Vladimirov, I., Castillón, G., Giles, et al.
Reproductive BioMedicine Online, 2020; 41(3):402-415

The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.

Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.
Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4. PMID:23756099

The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity.

Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C.
Fertil Steril. 2013 Feb;99(2):508-17. doi: 10.1016/j.fertnstert.2012.09.046. Epub 2012 Oct 23. PMID:23102856

A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature.

Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C.
Fertil Steril. 2011 Jan;95(1):50-60, 60.e1-15. doi: 10.1016/j.fertnstert.2010.04.063. Epub 2010 Jul 8. PMID:20619403

FAQs

Opening hours, contact details, lab address...

User manual

If you're a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services

EndomeTRIO

EndomeTRIO

A new dimension of endometrial health

More information
EMMA Endometrial Microbiome Metagenomic

EMMA

Evaluates the endometrium at the microbiological level

More information

ALICE

Detects the bacteria causing chronic endometritis

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information